Licensing deals

Pharma

Lilly-InnoCare, Elevar, China's 5-year plan—Fierce Pharma Asia

Lilly and InnoCare inked a potential $3.35 billion deal. The FDA approved a novel cancer drug in a first for Korea. China set an ambitious five-year plan.

Angus Liu Sep 25, 2026 9:38am

US' China deal policy, WCLC, Legend CEO—Fierce Pharma Asia

Sep 18, 2026 10:20am

Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia

Aug 28, 2026 9:00am

Fierce Biotech

Why a congressman says China is 'beating us on our ground game'

Aug 25, 2026 9:45am

Merck prepares expanded access to monthly PrEP pill early

Jul 24, 2026 10:40am

GSK-Hansoh, Merck-Kelun, AZ-Dizal—Fierce Pharma Asia

Jul 17, 2026 9:38am